ABSTRACT
Background High grade serous ovarian carcinoma (HGSOC) is the most common type of ovarian cancer; most patients experience disease recurrence which accumulates chemoresistance, leading to treatment failure. Previous investigations have characterised HGSOC at the genomic and transcriptomic level, identifying subtypes of patients with differential outcome and treatment response. However, the relationship between molecular events identified at the gene sequence, gene copy number and gene expression levels remains poorly defined.
Methods We perform multi-layer molecular characterisation of a large retrospective HGSOC cohort (n=362) with detailed clinical annotation to interrogate the relationship between patient groups defined by gene mutation, copy number events, gene expression patterns and infiltrating immune cell burden. We construct a high resolution picture of the molecular landscape in HGSOC and identify features of tumours associated with distinct clinical behaviour in patients.
Results BRCA2-mutant (BRCA2m) and EMSY-overexpressing cases demonstrated prolonged survival (multivariable hazard ratio 0.40 and 0.53) and higher chemotherapy response rates at first- and second-line treatment. CCNE1-gained (CCNE1g) cases demonstrated shorter survival (multivariable hazard ratio 1.52, 95% CI 1.10-2.10), under-representation of FIGO stage IV cases (P=0.017) and no significant difference in treatment response. We demonstrate marked overlap between the TCGA- and derived subtypes: the TCGA DIF, IMR, PRO and MES subtypes correlated with the Tothill C4, C2, C5 and C1 subtypes (P<0.001). IMR/C2 cases displayed higher BRCA1/2m frequency (25.5% and 32.5%) and significantly greater infiltration of immune cells (P<0.001), while PRO/C5 cases had the highest CCNE1g rate (23.9% and 22.2%) and were uniformly low in immune cell infiltration. The survival benefit for cases with aberrations in homologous recombination repair (HRR) genes was apparent across all transcriptomic subtypes (hazard ratio range 0.48-0.68). There was significant co-occurrence of RB loss and HRR gene aberrations (P=0.005); RB loss was further associated with favourable survival within cases harbouring HRR aberrations (multivariable hazard ratio 0.50, 95% CI 0.30-0.84).
Conclusions These data paint a high resolution picture of the molecular landscape in HGSOC, better defining patients who may benefit most from specific molecular therapeutics and highlighting those for whom novel treatment strategies are needed to improve outcomes.
Competing Interest Statement
RLH: consultancy fees from GSK outside the scope of this work. AMM: none. COM: none. TR: none. MC: none. IC: none. AHP: none. WGM: none. ARWW: consultancy fees from Bayer and Mithra outside the scope of this work. CB: none. YI: none. AO: none. BD, JCB, RM: employees and stockholders of AstraZeneca. AM: employee and stockholder of AstraZeneca during the course of this work, and employee of GSK. PR: grants from AstraZeneca during the conduct of this work, grants from AstraZeneca outside of this work, personal fees from AstraZeneca and GlaxoSmithKline/Tesaro outside of this work. CAS: none. DPH and RK: employees of Almac Diagnostics. CSH: none. CG: grants from AstraZeneca during the conduct of this study, personal fees from MSD, GSK, Tesaro, Clovis, Roche, Foundation One, Chugai, Takeda, Sierra Oncology and Cor2Ed outside the submitted work, patents PCT/US2012/040805 issued, PCT/GB2013/053202 pending, 1409479.1 pending, 1409476.7 pending, and 1409478.3 pending.
Funding Statement
RLH was supported by an MRC-funded fellowship (I171113-1019) and received funding from Target Ovarian Cancer, Tenovus Scotland (E19-11) and the Nicola Murray Foundation during the course of this work. AMM and CAS received core funding from the UK Medical Research Council to the MRC Human Genetics Unit (MC_UU_00007/16). COM received funding from The Melville Trust for Care and Cure of Cancer. Sample collection was supported by Cancer Research UK Experimental Cancer Medicine Centre funding. TR was supported by core funding from CRUK awarded to the CRUK Edinburgh Centre. The genomic characterisation of this cohort was funded by a research grant from AstraZeneca.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was obtained from South East Scotland Human Annotated Bioresource (Lothian NRS Bioresource Ethics Committee reference 15/ES/0094-SR705 and SR752). The need for consent was waived by the ethics committee due to the retrospective nature of the study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
